Brought to you by 
Cephalon buys two CTI divisions
22 Oct 2019
Executive Summary
In connection with its separate purchase of Cell Therapeutics Inc.'s CTI Technologies Inc.’s leukemia drug Trisenox (arsenic trioxide), Cephalon Inc. (therapeutics for neurological diseases and cancer) has also agreed to acquire two Cell Therapeutics’ wholly-owned subsidiaries: PolaRx Biopharmaceuticals Inc. and Cell Therapeutics (UK) Ltd.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Includes Contract
- Intra-Biotech Deal
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Cephalon buys two CTI divisions
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice